CV Sciences GRAS

CV Sciences (OTCQB: CVSI) has announced the financial results of the third quarter, which ended on September 30, 2018. Sales for the quarter increased by 143% to $13.6 million and gross profits increased by 149% to $9.9 million. The company also recorded an adjusted EBITDA of $4.1 million, up from $3.2 million during the same quarter in the previous year. In a statement, CV Sciences CEO Joseph Dowling said that he was encouraged by the company’s strong returns and credits the growth in sales to increased demand for their leading product line, PlusCBD.

Comments

comments